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Nonspeciﬁc clinical presentation of non-infectious, immune-mediated pulmonary complications of
etanercept therapy makes the diagnosis difﬁcult. While bronchoalveolar lavage ﬂuid (BALF) cell analysis
is frequently used in diagnosing drug-induced lung disease, BALF patterns in etanercept-induced lung
injury (EILI) are not well established. Furthermore, previous reports of EILI diagnosis relied on trans-
bronchial or surgical lung biopsies. Here, we report two patients who developed pulmonary toxicity after
etanercept treatment. Both patients were diagnosed with EILI. While one patient presented with CD4þ-
predominant lymphocytic alveolitis (consistent with a sarcoid-like pattern), the other patient exhibited
a CD8þ-predominant pattern (consistent with hypersensitivity pneumonitis-like reaction). The different
BAL patterns were accompanied by distinct radiographic ﬁndings. Both patients signiﬁcantly improved
after etanercept discontinuation and corticosteroid initiation. We propose that EILI can present with
distinct immunologic and radiographic phenotypes. In addition, early BALF analysis with lymphocyte
immunophenotyping can further deﬁne the underlying immunologic abnormalities, and thereby, avoid
more invasive procedures.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Etanercept, a dimerized protein of the extracellular portion of
the human TNF-a receptor fused to the Fc portion of human IgG1, is
considered to be less immunogenic than other TNF-a antagonists.1
Nevertheless, with increased use of this drug in recent years,
several immune-mediated adverse effects have been described.
However, the mechanisms of pulmonary complications are
incompletely understood.
Bronchoalveolar lavage (BAL) is widely used in the evaluation of
immunosuppressed patients with respiratory abnormalities, and
allows for analysis of lung injury patterns in drug-induced lungjury; TNF-a, tumor necrosis
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-NC-ND license.disease.2 However, very few data exist about BAL cellular analysis in
etanercept-induced lung injury (EILI). Knowledge of BAL patterns in
EILI may allow for a better understanding of underlying pathogenic
processes in this disease. We present two cases of EILI in which
BAL cellular analysis with immunophenotyping 1) helped identify
distinct pathogenic mechanisms and 2) provided guidance for
treatment without a need for tissue biopsy.
2. Case reports
2.1. Case 1
A 59-year-old white male with psoriasis and psoriatic arthritis
presented with a one-month history of progressive dyspnea,
fatigue, subjective fever, and night sweats. He was a former smoker
and denied sick contacts, occupational/recreational exposure, or
travel outside the Midwest. He had no history of lung disease. Prior
therapy with methotrexate and oral corticosteroids was stopped
due to side effects. He was switched to weekly etanercept (50 mg
subcutaneously) 1.5 years prior to presentation, with good control
of his rash and arthritis. Physical examination revealed hypoxemia
(88e89% on 3 L O2) and bilateral ﬁne crackles. There were no
clinical features consistent with an articular or skin ﬂare. Chest CT
Table 1
Pulmonary function tests.
Patient 1 Patient 2
At diagnosis At follow-up
(8 weeks)
At diagnosis At follow-up
(8 weeks)
FEV1 L, (% predicted) 2.56 (85) 2.74 (91) 2.12(62) (L) 2.40 (73)
(baseline)
FVC L, (% predicted) 4.31 (108) 4.42 (111) 2.75(61) (L) 3.11 (77)
(baseline)
DLCO (% predicted) 54 (L) 86 (N) n/a n/a
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tree-in-bud opacities, and mediastinal lymphadenopathy (Fig. 1).
Serum, urine and BAL testing for bacterial, viral, fungal, and
mycobacterial infections, and tuberculin skin testing were negative.
Spirometry showed a mild obstructive ventilatory defect and
moderately decreased diffusing capacity (Table 1). BAL cell analysis
revealed a CD4þ-predominant lymphocytic alveolitis (Table 2). A
presumptive diagnosis of EILI was made. Etanercept was stopped.
Short term prednisone (0.5 mg/kg/day) was started with prompt
resolution of symptoms and improvement in spirometry.Table 2
Bronchoalveolar lavage cell analysis.
BAL ﬂuid analysis Normal values Patient 1 Patient 2
Total cells 13  2  104 345  104 960  104
% Macrophages 85  1.6 64 59
% Neutrophils 1.6  0.7 1 2
% Eosinophils 0.19  0.06 0 3
% Lymphocytes 1.5  2.5 35 36
% CD4:CD8 2.2  0.3 2.56 (H) 0.15 (L)2.2. Case 2
A 56-year-old white male with rheumatoid arthritis (RA) and
associated mild pulmonary ﬁbrosis (minimal basilar involvement
stable over several years) was referred for dyspnea, dry cough,
decreased exercise tolerance, and hypoxemia. Due to progression of
extra-pulmonary RA symptoms on prednisone (5 mg/day), hydrox-
ychloroquine (200 mg twice/day), and sulfasalazine (1000mg twice/
day), the latter two were stopped, and etanercept 50 mg subcuta-
neously weekly was added to the steroids four months before
presentation. Joint symptoms rapidly resolved and the RAwas under
control as determined by the rheumatologist. However, the patient
then developed increasing dyspnea with exertion. Spirometry
demonstrated worsening restrictive defect (Table 1) since a prior
study 6 months ago. Chest CT (Fig. 2) revealed increasing ground
glass opacities (GGOs) andworsening interstitial inﬁltrates. Bacterial,
viral, fungal ormycobacterial infections were ruled out. BAL revealed
a CD8þ-predominant lymphocytic alveolitis (Table 2), thought to
represent etanercept-induced hypersensitivity pneumonitis. Eta-
nercept was discontinued and prednisone increased to 30 mg/day.Fig. 1. Radiographs of patient 1. (A) Chest X-ray (CXR) at presentation shows diffuse bilate
reticular interstitial opacities, tree-in-bud opacities, mediastinal lymphadenopaty. In conju
etanercept-induced sarcoid-like reaction was made, and treatment with corticosteroids wa
opacities.The patient rapidly improved, with return to baseline lung function
(Table 1) and chest CT ﬁndings within 8 weeks.3. Discussion
We report two cases of EILI presenting with different BAL
immunologic and radiologic patterns. Patient 1 presented with
a CD4þ-positive lymphocytic alveolitis, interstitial opacities, and
mediastinal lymphadenopathy. In the face of negative infectious
work-up (BAL ﬂuid cytological and microbiologic analysis, fungalral micronodular disease. (B, C) Chest CT at presentation shows bilateral nodular and
nction with the ﬁndings of a CD4þ-predominant lymphocytic alveolitis, a diagnosis of
s initiated. (D) CXR at follow-up (6 weeks) shows resolution of diffuse micronodular
Fig. 2. Radiographs of patient 2. (A) Chest CT at baseline shows bibasilar micronodular disease with patchy GGO. (B) Chest CT at presentation shows worsening bilateral GGO and
reticulo-nodular opacities. In conjunction with the ﬁndings of a CD8þ-predominant lymphocytic alveolitis, a diagnosis of etanercept-induced hypersensitivity pneumonitis was
made, and corticosteroid dose was increased. (C) Chest CT at follow-up (8 weeks) revealed resolution of ground glass opacities, persistent subpleural micronodular opacities.
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(no skin or musculoskeletal ﬁndings), and lack of exposure to other
medications with potential pulmonary side effects (discontinuation
of methotrexate > 1.5 years), the clinical presentation was most
suggestive of a sarcoid-like syndrome.
Patient 2 exhibited a CD8þ-positive lymphocytic alveolitis with
GGOs and reticulo-nodular inﬁltrates suggestive of a hypersensi-
tivity pneumonits-like reaction. We reached this diagnosis by
excluding possible bacterial or granulomatous infections (BAL ﬂuid
cytological and microbiologic analysis, fungal serology); exacerba-
tion of the pre-existing pulmonary ﬁbrosis (clinically controlled RA;
stable CT and PFTs before introduction of etanercept; BAL ﬂuid
cellular analysis not suggestive of UIP/NSIP/COP, the common
presentations of RA-related pulmonary ﬁbrosis), and medication-
induced lung disease (discontinuation of sulfasalazine and
hydroxychloroquine > 4 months).
While the radiographic features of our patients are in agreement
with the published literature,3e5 BAL patterns in EILI are not well
deﬁned. In fact, only one case of CD8þ alveolitis associated with EILI
is reported.3 Interestingly, we did ﬁnd two reports of CD4þ-positive
lymphocytic alveolitis in EILI. However, both patients underwent
further invasive diagnostic biopsies (transbronchial or VATS) before
treatment with systemic steroids was started.6,7
Our report emphasizes that EILI can present with distinct BAL
immunologic patterns. We speculate that a sarcoid-like reaction
(patient 1) and a hypersensitivity pneumonitis-like reaction
(patient 2) represent two different, but steroid-sensitive, manifes-
tations of EILI. Interestingly, paradoxical granulomatous reactions
have been described before in patients receiving etanercept. These
reactions appear to be more common in patients with underlying
RA or psoriasis (as seen in our patients). A potential explanation is
less robust TNF binding and quicker TNF release8 by etanercept
than with other anti-TNF-a monoclonal antibodies. Subsequently
the residual TNF-a activity induces CD4þ Th1-cells activation and
increases production of IFN-a. The elevated IFN-a unopposed by an
optimal TNF-a activity enhances the survival and proliferation of
CD8þ blasts9 and IFN-g secretion from NK cells.10 In the presence of
Th1 environment IFN-g is a key event in granuloma formation.11 An
excess of various interferon (a and g) activity, a TNF-a-induced Th1
environment combined with increased susceptibility to airborne
antigens may explain paradoxical pulmonary CD4þ or CD8þ
granulomatous reaction seen in EILI.12
In previously reported EILI cases, the diagnosis was established
via open lung or transbronchial biopsies; BAL ﬂuid analysis was
used only to exclude infectious causes. Our report suggests that
analysis of BAL cell differential and lymphocyte subtyping may
obviate the need for tissue biopsy in EILI, and thereby, allows for
targeted therapy while avoiding the potential complications of
a more invasive procedure.In conclusion, EILI can present with CD4þ- or CD8þ-positive
lymphocytic alveolitis and distinct radiographic patterns, possibly
representing a sarcoid or a hypersensitivity reaction phenotype. In
either case, BAL cellular analysis may allow for correct diagnosis
and initiation of steroid therapy without a need for tissue biopsy.
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